SE9401709D0 - Improved alphavirus vectors for expression of heterologous DNA - Google Patents
Improved alphavirus vectors for expression of heterologous DNAInfo
- Publication number
- SE9401709D0 SE9401709D0 SE9401709A SE9401709A SE9401709D0 SE 9401709 D0 SE9401709 D0 SE 9401709D0 SE 9401709 A SE9401709 A SE 9401709A SE 9401709 A SE9401709 A SE 9401709A SE 9401709 D0 SE9401709 D0 SE 9401709D0
- Authority
- SE
- Sweden
- Prior art keywords
- expression
- alphavirus
- heterologous dna
- vectors
- alphavirus vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9401709A SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Improved alphavirus vectors for expression of heterologous DNA |
AU25826/95A AU698976B2 (en) | 1994-05-18 | 1995-05-17 | Alphavirus expression vector |
US08/737,608 US6224879B1 (en) | 1994-05-18 | 1995-05-17 | Alphavirus expression vector |
EP95920347A EP0760000B1 (fr) | 1994-05-18 | 1995-05-17 | Vecteur d'expression de l'alphavirus |
JP52958095A JP3786956B2 (ja) | 1994-05-18 | 1995-05-17 | アルファウイルス発現ベクター |
AT95920347T ATE352633T1 (de) | 1994-05-18 | 1995-05-17 | Expressionsvektor des alphavirus |
CA002188421A CA2188421A1 (fr) | 1994-05-18 | 1995-05-17 | Vecteur d'expression de l'alphavirus |
PCT/SE1995/000558 WO1995031565A1 (fr) | 1994-05-18 | 1995-05-17 | Vecteur d'expression de l'alphavirus |
DE69535376T DE69535376T2 (de) | 1994-05-18 | 1995-05-17 | Expressionsvektor des alphavirus |
FI964577A FI964577A (fi) | 1994-05-18 | 1996-11-15 | Alfavirusilmennysvektori |
US09/657,312 US6692750B1 (en) | 1994-05-18 | 2000-09-07 | Alphavirus expression vector |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9401709A SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Improved alphavirus vectors for expression of heterologous DNA |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9401709D0 true SE9401709D0 (sv) | 1994-05-18 |
Family
ID=20394041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9401709A SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Improved alphavirus vectors for expression of heterologous DNA |
Country Status (10)
Country | Link |
---|---|
US (2) | US6224879B1 (fr) |
EP (1) | EP0760000B1 (fr) |
JP (1) | JP3786956B2 (fr) |
AT (1) | ATE352633T1 (fr) |
AU (1) | AU698976B2 (fr) |
CA (1) | CA2188421A1 (fr) |
DE (1) | DE69535376T2 (fr) |
FI (1) | FI964577A (fr) |
SE (1) | SE9401709D0 (fr) |
WO (1) | WO1995031565A1 (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6458560B1 (en) | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
AU729690B2 (en) * | 1996-10-10 | 2001-02-08 | Henrik Garoff | Alphavirus-retrovirus vectors |
US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US6432699B1 (en) | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
KR100556864B1 (ko) | 1997-05-13 | 2006-03-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 렌티바이러스-기원 유전자 전달 벡터 |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
AU1013701A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
ES2276788T3 (es) | 2000-05-10 | 2007-07-01 | Sanofi Pasteur Limited | Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones. |
DE60135983D1 (de) | 2000-05-31 | 2008-11-13 | Novartis Vaccines & Diagnostic | Verfahren zur reinigung von alphaviralen replikon partikeln |
US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
AU2001290642A1 (en) | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
ATE460472T1 (de) | 2000-12-08 | 2010-03-15 | Life Technologies Corp | Verfahren und zusammensetzungen zur synthese von nukleinsäuremolekülen unter verwendung multipler erkennungsstellen |
CN1520303B (zh) * | 2001-03-27 | 2013-04-24 | 纽约大学 | 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗 |
ATE437222T1 (de) | 2001-09-06 | 2009-08-15 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
WO2003085087A2 (fr) | 2002-04-09 | 2003-10-16 | Aventis Pasteur, Limited | Acide nucleique d'antigene carcinoembryonnaire modifie et vecteurs d'expression |
US6899507B2 (en) * | 2002-02-08 | 2005-05-31 | Asm Japan K.K. | Semiconductor processing apparatus comprising chamber partitioned into reaction and transfer sections |
EP1386926A1 (fr) * | 2002-07-29 | 2004-02-04 | Bioxtal | Procédés de préparation de polypeptides marqués recombinants et leur utilisation |
DK1585812T3 (en) | 2002-12-13 | 2017-04-10 | Alphavax Inc | MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES |
ES2552687T3 (es) * | 2002-12-13 | 2015-12-01 | Alphavax, Inc. | Partículas alfavíricas y métodos de preparación |
JP2006517790A (ja) * | 2003-01-09 | 2006-08-03 | インヴィトロジェン コーポレーション | ポリペプチド−核酸複合体の細胞の送達および活性化 |
WO2004085660A2 (fr) | 2003-03-20 | 2004-10-07 | Alphavax, Inc. | Replicons d'alphavirus ameliores et produits de recombinaison auxiliaires |
AU2004257214B2 (en) | 2003-07-11 | 2010-04-22 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
US7910093B2 (en) | 2003-08-19 | 2011-03-22 | New York University | Method for detecting cancer cells and monitoring cancer therapy |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
EP1745074A2 (fr) * | 2004-04-29 | 2007-01-24 | The University of North Carolina at Chapel Hill | Procedes et compositions pour ameliorer les proprietes d'adhesion cellulaire |
DE602005012382D1 (de) | 2004-05-18 | 2009-03-05 | Alphavax Inc | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren |
CA2572921C (fr) | 2004-07-09 | 2017-01-03 | The University Of North Carolina At Chapel Hill | Adjuvants viraux de l'encephalite equine du venezuela a defaut de propagation et competents pour la replication |
AU2006302794B2 (en) * | 2005-02-15 | 2011-08-04 | Children's Hospital, Inc. | New live virus vaccines |
US7303898B2 (en) * | 2005-03-29 | 2007-12-04 | New York University | Defective sindbis viral vectors |
US20100233209A1 (en) * | 2005-08-11 | 2010-09-16 | Higgs Stephen T | Chikungunya virus infectious clones and uses therefor |
WO2008127486A2 (fr) * | 2006-12-29 | 2008-10-23 | Bacilligen, Inc. | Capsides à arndb capables de réplication et leurs utilisations |
AU2008266807B2 (en) | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
RU2010152562A (ru) * | 2008-05-23 | 2012-06-27 | Фит Байотек Ой (Fi) | Векторы экспрессии, кодирующие репликазу альфавируса, и их применение в качестве иммунологического адьюванта |
CA3020426A1 (fr) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Systemes de replicon d'arterivirus recombinant et utilisations correspondantes |
US11364310B2 (en) | 2016-10-17 | 2022-06-21 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
EP3548625B1 (fr) * | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions et méthodes d'activation d'expression génique |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
AU2019210189A1 (en) | 2018-01-19 | 2020-08-06 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
SE9003978D0 (sv) * | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
GB9406498D0 (en) | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
-
1994
- 1994-05-18 SE SE9401709A patent/SE9401709D0/xx unknown
-
1995
- 1995-05-17 EP EP95920347A patent/EP0760000B1/fr not_active Expired - Lifetime
- 1995-05-17 JP JP52958095A patent/JP3786956B2/ja not_active Expired - Fee Related
- 1995-05-17 CA CA002188421A patent/CA2188421A1/fr not_active Abandoned
- 1995-05-17 AU AU25826/95A patent/AU698976B2/en not_active Ceased
- 1995-05-17 WO PCT/SE1995/000558 patent/WO1995031565A1/fr active IP Right Grant
- 1995-05-17 AT AT95920347T patent/ATE352633T1/de not_active IP Right Cessation
- 1995-05-17 US US08/737,608 patent/US6224879B1/en not_active Expired - Fee Related
- 1995-05-17 DE DE69535376T patent/DE69535376T2/de not_active Expired - Fee Related
-
1996
- 1996-11-15 FI FI964577A patent/FI964577A/fi unknown
-
2000
- 2000-09-07 US US09/657,312 patent/US6692750B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE352633T1 (de) | 2007-02-15 |
EP0760000A1 (fr) | 1997-03-05 |
US6692750B1 (en) | 2004-02-17 |
WO1995031565A1 (fr) | 1995-11-23 |
US6224879B1 (en) | 2001-05-01 |
CA2188421A1 (fr) | 1995-11-23 |
DE69535376T2 (de) | 2007-11-08 |
FI964577A0 (fi) | 1996-11-15 |
JP3786956B2 (ja) | 2006-06-21 |
DE69535376D1 (de) | 2007-03-15 |
JPH10500017A (ja) | 1998-01-06 |
AU2582695A (en) | 1995-12-05 |
AU698976B2 (en) | 1998-11-12 |
FI964577A (fi) | 1996-11-15 |
EP0760000B1 (fr) | 2007-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9401709D0 (sv) | Improved alphavirus vectors for expression of heterologous DNA | |
AU2155795A (en) | Alphavirus cdna vectors | |
DE69637660D1 (de) | Verfahren zür einführung und expression von genen in tierischen zellen | |
FR2681786B1 (fr) | ||
AU2001254624A1 (en) | Human coagulation factor vii variants | |
HK1024714A1 (en) | Dumbbell expression constructs for gene therapy | |
BR9913331A (pt) | Expressão e exportação de inibidores de angiogênese como imunofusinas | |
MY134810A (en) | Targeted gene expression of thrombopoietein, dnase i and b-interferon | |
DE69928745D1 (de) | Uracyl-phosphoribosyltransferase mutante | |
IL72643A (en) | Gene encoding an analog of human interleukin-ii which substantially retains the biological activity of natural human interleukin-ii,microorganism expression vector containing the gene,microorganisms transformed by the vector and the human interleukin-ii analog produced by the microorganisms | |
IL122120A (en) | Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome | |
DE69518910D1 (de) | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle | |
DK1681355T3 (da) | Sekvensspecifik DNA-rekombination i eukaryote celler | |
TR199802648A2 (xx) | Gen tedavisi i�in n�klein asit yap�lar�. | |
EP0804613A4 (fr) | Genes suppresseurs de tumeurs, proteines codees par ces derniers et utilisation desdits genes et proteines | |
DK0596881T3 (da) | Ekspression i ikke-tumurale humane lymofoblastoider med en integrativ vektor | |
DE3852006D1 (de) | Expressionsvektor zur regulierbaren expression von fremdgenen in prokaryonten. | |
ATE162853T1 (de) | Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung | |
PL344766A1 (en) | Recombined dna sequence, vector incorporating such recombined dna sequence, proteins obtained by expression of that recombined dna sequence and micro-organism's or plant's cell or their protoplasts transformed by that recombined dna sequence |